Oxcarbazepin Orion

Oxcarbazepin Orion helps control 'overstimulated' nerve cells in the brain, thereby preventing or reducing the frequency of epileptic seizures.

Form
tabletti, kalvopäällysteinen
Strength
600 mg
Active Ingredient
Oxcarbazepine
Manufacturer
Orion Corporation

How to Use

Dosage

The usual starting dose for adults is 600 mg per day; for children aged 6 years and older, the starting dose is 8–10 mg/kg per day, divided into two doses.

Method

Swallow tablets with a little water, taking them twice a day at roughly the same time; tablets can be halved to make swallowing easier, but not to divide into equal doses.

Important

The optimal daily dose for adults is typically between 600–2400 mg; for children, the maximum daily dose is 46 mg/kg.

Possible Side Effects

COMMON
  • Fatigue, headache, dizziness, drowsiness, nausea, vomiting, double vision, weakness, memory problems, difficulty concentrating, apathy, agitation, confusion, blurred vision, visual disturbances, constipation, diarrhea, stomach pain, acne, hair loss, balance disorders, weight gain, speech disorders, tremor, coordination problems, involuntary eye movements, anxiety, nervousness, depression, mood swings, rash.
RARE
  • Weight gain, hair loss, muscle weakness, feeling cold (signs of underactive thyroid), falls, high blood pressure, hives, swelling of lips, eyelids, face, throat, or mouth with breathing, speaking or swallowing difficulties (signs of severe allergic reaction like anaphylaxis and angioedema), rash and/or fever (DRESS; AEGP), fatigue, shortness of breath during exertion, paleness, headache, chills, dizziness, frequent feverish infections, sore throat, mouth ulcers, unusual tendency to bruise or bleed, nosebleeds, red or bluish spots on the skin or unexplained skin changes (signs of reduced platelets or blood cells), pathological sleepiness, confusion, muscle twitching or significantly worsened seizures (signs of low blood sodium), hypersensitivity symptoms like rash, fever or muscle and joint pain, severe blistering changes on skin and/or mucous membranes of lips, eyes, mouth, nose or genitals (signs of severe allergic reaction, Lyell's syndrome, Stevens-Johnson syndrome and erythema multiforme), red, patchy rash mainly on the face with fatigue, fever, nausea or loss of appetite (signs of systemic lupus erythematosus), flu-like symptoms with yellowing of the skin or whites of the eyes (signs of liver disease), severe upper abdominal pain, vomiting, loss of appetite (signs of pancreatitis), bone disorders such as osteopenia and osteoporosis (weakening of bones) and fractures, irregular heartbeat or very fast or slow heart rate.

Important Warnings

  • Seek immediate medical attention if you develop a severe allergic reaction, such as swelling of your lips, eyelids, face, or throat, sudden breathing difficulties, fever with swollen lymph nodes, or a severe skin rash.
  • Contact your doctor if you experience symptoms of liver inflammation, such as yellowing of your skin or the whites of your eyes.
  • Inform your doctor if your seizure frequency increases, which can occur in both children and adults.
  • Consult a doctor immediately if you notice symptoms of blood disorders like unusual fatigue, shortness of breath, paleness, frequent infections, easy bruising or bleeding.
  • Seek immediate medical help if you have thoughts of harming yourself or suicide.
Show 3 more warnings
  • Contact your doctor if your heart rate becomes unusually fast or slow.
  • Do not use this medicine if you are allergic to oxcarbazepine, eslicarbazepine, or any other ingredient listed in the leaflet.
  • If you are a woman using hormonal birth control, be aware that Oxcarbazepin Orion can make it less effective; consider using a non-hormonal contraception method.

Use in Elderly Patients

Category C

Suitable for older adults, with specific precautions. Reduce the dose in severe renal impairment. Numerous potential adverse effects, such as hyponatraemia, hematological changes and risk of hepatic injury. May increase the need for a vitamin D supplement. (updated 10.11.2025)